Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2035969 | 0.96 | TSHR (0.46) | TSHRTHRBSMPD1POLBAPEX1 | |
| SCHEMBL2036004 | 0.95 | TSHR (0.48) | TSHRTHRBSMPD1POLBAPEX1 | |
| SCHEMBL541534 | 0.92 | THRB (0.40) | TSHRTHRBALDH1A1 | |
| SCHEMBL2039814 | 0.90 | TSHR (0.44) | TSHRTHRBSMPD1POLBAPEX1 | |
| SCHEMBL2036202 | 0.89 | TSHR (0.47) | TSHRTHRBSMPD1POLBAPEX1 | |
| SCHEMBL2038042 | 0.89 | TSHR (0.42) | TSHRTHRBSMPD1POLBAPEX1 | |
| SCHEMBL3654903 | 0.89 | TSHR (0.42) | TSHRTHRBSMPD1POLBAPEX1 | |
| SCHEMBL541861 | 0.87 | TSHR (0.42) | TSHRTHRBSMPD1POLBAPEX1 | |
| SCHEMBL3653087 | 0.86 | TSHR (0.47) | TSHRTHRBSMPD1POLBAPEX1 | |
| SCHEMBL2039638 | 0.85 | TSHR (0.49) | TSHRTHRBSMPD1POLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130034509-A1 | COSMETIC TREATMENT METHOD INVOLVING A COMPOUND CAPABLE OF CONDENSING IN SITU | L'OREAL (FR) | 2013-02-07 | — | — | US | disclosed |
| EP-2512416-A2 | COSMETIC TREATMENT METHOD INVOLVING A COMPOUND CAPABLE OF CONDENSING IN SITU | L'Oréal (FR) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073279-A2 | COSMETIC TREATMENT METHOD INVOLVING A COMPOUND CAPABLE OF CONDENSING IN SITU | L'OREAL (FR) | 2011-06-23 | — | — | WO | disclosed |
| US-20100203004-A1 | COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER | L'OREAL (FR) | 2010-08-12 | — | — | US | disclosed |
| EP-2205197-A1 | COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER | L'Oreal (FR) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009056545-A1 | COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER | L'OREAL (FR) | 2009-05-07 | — | — | WO | disclosed |
| EP-1764078-B1 | Microcapsules with aqueous core and their use in cosmetic compositions | OREAL (FR) | 2008-05-14 | — | — | EP | disclosed |
| EP-1764078-A1 | Microcapsules with aqueous core and their use in cosmetic compositions | L'OREAL (FR) | 2007-03-21 | — | — | EP | disclosed |
| EP-1163905-A1 | SKIN PREPARATIONS FOR EXTERNAL USE | NOF CORPORATION (JP) | 2001-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130034509-A1 | COSMETIC TREATMENT METHOD INVOLVING A COMPOUND CAPABLE OF CONDENSING IN SITU | POLR1C, CUTA, MITF | TSHR 3797/4885THRB 4619/4885SMPD1 621/4885 |
| US-20100203004-A1 | COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER | PHOSPHO1, CUTA, SGMS1 | TSHR 3000/4885THRB 3607/4885SMPD1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.